Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker

He, Yingchun; Shen, Yi; Cao, Yu; Tang, Fang-Qing; Tian, Daofa; Huang, Chenfei; Tao, Huai; Zhou, Fangliang; Zhang, Bo; Song, Lan; He, Long; Lin, Limei; Lü, Fang; Liao, Duan‐Fang; Cao, Deliang

doi:10.3233/cbm-150548

Cited by 20 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we have found that both AKR1B10 protein and mRNA levels were reduced in most of NPC tumors compared with para-carcinoma and benign tissues, which further suggests that AKR1B10 expression is down-regulated in the digestive tract cancers. He et al [ 32 ] also investigated that AKR1B10 expression levels in NPC tissues are lower than that in benign tissues, which is consistent to our results. However, in their studies, AKR1B10 expression levels are higher in NPC tissues than that in normal nasopharyngeal tissues of healthy people [ 32 ], which was not observed in our studies because it was too difficult to obtain normal nasopharyngeal tissues from healthy persons.…”

Section: Discussionsupporting

confidence: 92%

Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma

Guo

Luo

et al. 2016

Cell Biosci

View full text Add to dashboard Cite

BackgroundNasopharyngeal carcinoma (NPC) is one of the most common human head and neck cancers with high incidence in Southern China, Southeast Asia and North Africa. Because of its nonspecific symptoms, the early diagnosis of NPC is very difficult. The 5-year survival rate is not ideal in spite of great innovations in radiation and chemotherapy treatments. Highly sensitive and specific prognostic biomarkers are eager for NPC clinical diagnosis. To find specific target molecules is very important for individualized treatment. Aldo–keto reductase B10 (AKR1B10) is closely related to tumorigenesis and tumor development, and however, its expression level in NPC tissues is not clear.ResultsAKR1B10 expression levels were validated in benign, para-cancerous nasopharyngeal and NPC tissues by immunohistochemical evaluation. AKR1B10 was positively expressed in 42 (82.4 %) of 51 benign specimens, and 235 (98.7 %) of 238 para-carcinoma specimens. This percentage was significantly higher than 44.5 % (133/299) in nasopharyngeal carcinoma tissue (p < 0.01). AKR1B10 mRNA quantitative levels detected by real-time quantitative RT-PCR in 90 NPC tissue samples (0.10 ± 0.21) were significantly lower than that in 15 benign tissue samples (1.03 ± 1.12) (p < 0.01). AKR1B10 expression levels in NPC were correlated negatively with T-classification, lymph node metastasis (p < 0.05). We established nasopharyngeal cancer monoclonal cells CNE-2/AKR1B10 with AKR1B10 stable expression and CNE-2/vector cells without AKR1B10 expression by using a modified lentivirus-mediated method, and found that AKR1B10 inhibited the proliferation of CNE-2/AKR1B10 cells by using MTT assay and flow cytometry, and cell migration by in vitro scratch test.ConclusionTaken together, our data suggest that low expression of AKR1B10 is an independent prognostic indicator in nasopharyngeal carcinoma, and that AKR1B10 may be involved in regulating the proliferation and migration of nasopharyngeal cancer cells.

show abstract

Section: Discussionsupporting

confidence: 92%

Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma

Guo

Luo

et al. 2016

Cell Biosci

View full text Add to dashboard Cite

show abstract

“…By contrast, AKR1B10 expression has been reported as an independent variable of favorable prognosis in 3 studies of colorectal, gastric, and nasopharyngeal carcinomas . It is of interests to note that He et al found AKR1B10 expression levels are higher in nasopharyngeal carcinoma (NPC) tissues compared with the normal nasopharyngeal tissues. In NPC tissues, AKR1B10 expression seemed high specifically in SCC, but low in basal cell carcinoma, adenoid cystic carcinoma, adenocarcinoma, and undifferentiated carcinoma.…”

Section: Discussionmentioning

confidence: 99%

“…[6][7][8][9] Elevated expression of AKR1B10 is found in a wide variety of human tumors, such as hepatocellular, 6,11,12 nonsmall cell lung, 13 breast, 14 cervical, 15 pancreatic, 16 and nasopharyngeal carcinomas. 17 Conversely, the expression of AKR1B10 is downregulated gastric, 18 colon, 19 and head and neck cancers. 20 AKR1B10 may exert disparate functions in tumorigenesis dependent upon the cellular context.…”

Section: Introductionmentioning

confidence: 99%

Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma

Cheng

Lee

et al. 2017

Head & Neck

View full text Add to dashboard Cite

show abstract

“…[5][6][7] Elevated expression of AKR1B10 is found in nonsmall cell lung, hepatocellular, nasopharyngeal, cervical, pancreatic, and breast carcinomas. [8][9][10][11][12][13] Furthermore, it has been considered a valuable prognostic marker for hepatocellular, 9 cervical, 11 and breast 13 cancers. Recently, we demonstrated that a higher mean AKR1B10 labeling score, as assessed using immunochemical staining, is significantly associated with an advanced TNM classification and shorter survival in patients with OSCC.…”

Section: Introductionmentioning

confidence: 99%

Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma

Peng

Cheng

et al. 2018

Head & Neck

View full text Add to dashboard Cite

Background Aldo‐keto reductase family 1 member B10 (AKR1B10) expression in oral squamous cell carcinoma (OSCC) tissue specimens is correlated with the progression and prognosis of OSCC. Methods Saliva samples were obtained from 35 normal controls and 86 patients with OSCC before cancer surgery. The AKR1B10 levels were determined using enzyme‐linked immunosorbent assay (ELISA). Results The mean salivary AKR1B10 levels were significantly higher in the patients with OSCC than in the normal controls (P < .001). Higher salivary AKR1B10 levels were significantly associated with larger tumor size, more advanced clinical stage, and areca quid chewing habit. Patients with OSCC with a higher salivary AKR1B10 level (>646 pg/mL) had a significantly poorer survival than those with a lower (≤646 pg/mL) salivary AKR1B10 level (P = .026). Conclusion The salivary AKR1B10 level may be a promising biomarker for screening high‐risk patients with OSCC and monitoring the progression of OSCC.

show abstract

Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker

Abstract: AKR1B10 is overexpressed in nasopharyngeal hyperplasia, benign tumors, and carcinomas, being a potential new biomarker.

Cited by 20 publications

References 0 publications

Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma

Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma

Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma

Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma

Contact Info

Product

Resources

About